Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Retained Earnings: 2023-2025

Historic Retained Earnings for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to -$309.8 million.

  • Artiva Biotherapeutics' Retained Earnings fell 34.35% to -$309.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$309.8 million, marking a year-over-year decrease of 34.35%. This contributed to the annual value of -$246.7 million for FY2024, which is 36.06% down from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Retained Earnings of -$309.8 million as of Q3 2025, which was down 7.48% from -$288.2 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Retained Earnings high stood at -$181.3 million for Q4 2023, and its period low was -$309.8 million during Q3 2025.
  • For the 3-year period, Artiva Biotherapeutics' Retained Earnings averaged around -$248.1 million, with its median value being -$246.7 million (2024).
  • Data for Artiva Biotherapeutics' Retained Earnings shows a maximum YoY crashed of 36.06% (in 2024) over the last 5 years.
  • Over the past 3 years, Artiva Biotherapeutics' Retained Earnings (Quarterly) stood at -$181.3 million in 2023, then crashed by 36.06% to -$246.7 million in 2024, then tumbled by 34.35% to -$309.8 million in 2025.
  • Its last three reported values are -$309.8 million in Q3 2025, -$288.2 million for Q2 2025, and -$267.0 million during Q1 2025.